GO:0003874 6-pyruvoyltetrahydropterin synthase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003874 describes the catalytic activity of 6-pyruvoyltetrahydropterin synthase (PTPS), which converts 7,8-dihydroneopterin 3'-triphosphate to 6-pyruvoyl-5,6,7,8-tetrahydropterin, releasing triphosphate and a proton.
• PTPS is a key enzyme in the de novo biosynthesis of tetrahydrobiopterin (BH4), an essential cofactor for aromatic amino acid hydroxylases and nitric oxide synthases.
• Human PTPS is regulated at both the mRNA and protein levels, including by cytokines and reversible S-glutathionylation.
• Bacterial PTPS homologues can have distinct catalytic activities, such as converting sepiapterin to 7,8-dihydropterin, and some function in folate biosynthesis rather than BH4 synthesis.
• Dysregulation of PTPS activity is linked to BH4 deficiency disorders, endothelial dysfunction, and neurological conditions.
• CRISPR-based knockout, point mutation, and knock-in models enable precise interrogation of PTPS function in health and disease.
Description
6-pyruvoyltetrahydropterin synthase (PTPS) is a metalloenzyme that catalyzes the second step in the de novo biosynthesis of tetrahydrobiopterin (BH4), a critical cofactor for phenylalanine, tyrosine, and tryptophan hydroxylases as well as nitric oxide synthases. The reaction mediated by PTPS, defined by GO:0003874, converts 7,8-dihydroneopterin 3'-triphosphate into 6-pyruvoyl-5,6,7,8-tetrahydropterin, releasing triphosphate and a proton. This activity is essential for maintaining BH4 homeostasis, and its dysregulation has been implicated in metabolic and cardiovascular disorders. Researchers study PTPS to understand BH4-related pathologies, to characterize species-specific differences in pterin metabolism, and to develop therapeutic strategies targeting BH4 biosynthesis.
6-pyruvoyltetrahydropterin synthase activity At A Glance
| GO ID | GO:0003874 |
|---|---|
| GO term | 6-pyruvoyltetrahydropterin synthase activity |
| Ontology | molecular_function |
| Synonym | PTPS activity; 6-pyruvoyl tetrahydrobiopterin synthase activity; 2-amino-4-oxo-6-[(1S,2R)-1,2-dihydroxy-3-triphosphooxypropyl]-7,8-dihydroxypteridine triphosphate lyase activity |
| Major function | Catalyzes the conversion of 7,8-dihydroneopterin 3'-triphosphate to 6-pyruvoyl-5,6,7,8-tetrahydropterin, a step in tetrahydrobiopterin biosynthesis. |
| Reaction | 7,8-dihydroneopterin 3'-triphosphate = 6-pyruvoyl-5,6,7,8-tetrahydropterin + H+ + triphosphate |
| Cofactor | Zinc ion (implied by enzyme family, but not explicitly stated in provided citations) |
| Subcellular location | Cytosol (typical for BH4 biosynthesis enzymes, but not explicitly stated in provided citations) |
| Pathway | Tetrahydrobiopterin biosynthesis (KEGG pathway map00790, not explicitly cited) |
What Is GO:0003874?
GO:0003874, 6-pyruvoyltetrahydropterin synthase activity, is a molecular function defined as the catalysis of the reaction: 7,8-dihydroneopterin 3'-triphosphate = 6-pyruvoyl-5,6,7,8-tetrahydropterin + H+ + triphosphate. In simpler terms, it is the enzyme activity that removes a triphosphate group from 7,8-dihydroneopterin 3'-triphosphate and rearranges the remaining molecule to form 6-pyruvoyl-5,6,7,8-tetrahydropterin, a key intermediate in tetrahydrobiopterin synthesis.
Why Is 6-pyruvoyltetrahydropterin synthase activity Important in Cell Biology?
PTPS activity is indispensable for the production of tetrahydrobiopterin (BH4), a cofactor required for the synthesis of neurotransmitters such as dopamine and serotonin, and for the regulation of vascular tone via nitric oxide synthases. Consequently, alterations in PTPS function can lead to BH4 deficiency, which manifests as hyperphenylalaninemia, neurological impairment, and endothelial dysfunction. Understanding PTPS regulation and its structural diversity across species also informs antimicrobial drug discovery, as some pathogens rely on PTPS homologues for folate synthesis.
• PTPS is essential for BH4 biosynthesis, which is required for aromatic amino acid hydroxylases and nitric oxide synthases.
• Deficiency in PTPS activity causes BH4-deficient hyperphenylalaninemia, a treatable form of phenylketonuria.
• PTPS expression and activity are regulated by cytokines in human vascular endothelial cells, linking inflammation to BH4 availability.
• Reversible S-glutathionylation of human PTPS protects its enzymatic activity under oxidative stress.
• Bacterial PTPS homologues can participate in folate biosynthesis, making them potential antibiotic targets.
• Structural differences between mammalian and bacterial PTPS enzymes can be exploited for selective inhibitor design.
• PTPS activity influences endothelial function and cardiovascular health through BH4-dependent nitric oxide production.
• PTPS is a model enzyme for studying metalloenzyme catalysis and allosteric regulation.
Molecular Mechanism of 6-pyruvoyltetrahydropterin synthase activity
Substrate Binding and Catalysis
In simple terms: The enzyme grabs a molecule called 7,8-dihydroneopterin 3'-triphosphate and transforms it into another molecule called 6-pyruvoyl-5,6,7,8-tetrahydropterin.
PTPS catalyzes the elimination of triphosphate from 7,8-dihydroneopterin 3'-triphosphate, yielding 6-pyruvoyl-5,6,7,8-tetrahydropterin, a reaction that is central to BH4 biosynthesis. The enzyme likely employs a zinc ion for substrate activation, although the provided citations do not explicitly detail the metal coordination.
Structural Features of PTPS
In simple terms: The enzyme has a specific 3D shape that allows it to recognize its substrate and perform the chemical reaction.
Crystal structures of bacterial PTPS homologues reveal a conserved fold that accommodates the pterin substrate, and some homologues exhibit distinct catalytic activities compared to mammalian PTPS. These structural insights help explain substrate specificity and guide inhibitor design.
Regulation by S-Glutathionylation
In simple terms: A chemical modification called S-glutathionylation can attach to the enzyme and protect it from damage, but it also affects its activity.
Human PTPS undergoes reversible S-glutathionylation, which protects its enzymatic activity under oxidative stress conditions. This modification represents a regulatory mechanism that fine-tunes BH4 synthesis in response to cellular redox status.
Species-Specific Variations
In simple terms: Bacteria have similar enzymes that can do different jobs, sometimes helping to make vitamins instead of BH4.
Bacterial PTPS orthologs, such as those encoded by ygcM in Escherichia coli, can convert sepiapterin to 7,8-dihydropterin, a reaction distinct from mammalian PTPS activity. Some bacterial PTPS paralogs replace dihydroneopterin aldolase in folate biosynthesis, highlighting functional diversity.
Key Genes Involved in GO:0003874 6-pyruvoyltetrahydropterin synthase activity
The following genes and proteins are directly associated with 6-pyruvoyltetrahydropterin synthase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTS (human) | Encodes 6-pyruvoyltetrahydropterin synthase, catalyzing the second step in BH4 biosynthesis | Mutations cause BH4-deficient hyperphenylalaninemia; target for therapeutic modulation |
| PTS (bacterial, e.g., ygcM) | Ortholog with sepiapterin conversion activity | Model for studying enzyme evolution and antibiotic targets |
| PTPS paralogs (bacteria) | Replace dihydroneopterin aldolase in folate synthesis | Potential targets for antimicrobials |
| PTPS (Plasmodium) | Atypical orthologue linking folate biosynthesis | Malaria drug discovery |
| PTPS (dual domain bacteria) | Responsible for BH4 synthesis in bacteria | Understanding BH4 pathways in prokaryotes |
| GCH1 | GTP cyclohydrolase I, first enzyme in BH4 synthesis | Upstream regulator of PTPS substrate availability |
| SPR | Sepiapterin reductase, downstream enzyme in BH4 synthesis | Complements PTPS in BH4 pathway |
| NOS1 | Neuronal nitric oxide synthase, uses BH4 | BH4-dependent signaling |
| NOS2 | Inducible nitric oxide synthase, uses BH4 | Inflammation-related BH4 consumption |
| NOS3 | Endothelial nitric oxide synthase, uses BH4 | Vascular function |
| PAH | Phenylalanine hydroxylase, uses BH4 | Phenylketonuria and BH4 deficiency |
| TH | Tyrosine hydroxylase, uses BH4 | Dopamine synthesis |
| TPH1 | Tryptophan hydroxylase 1, uses BH4 | Serotonin synthesis |
| TPH2 | Tryptophan hydroxylase 2, uses BH4 | Serotonin synthesis in brain |
| GCH1 (feedback) | Regulated by BH4 | Feedback regulation of BH4 pathway |
| PTPS (human, S-glutathionylated) | Modified form with altered activity | Redox regulation |
| PTPS (human, cytokine-induced) | mRNA and activity induced by cytokines | Inflammation and endothelial function |
| PTPS (bacterial, structural) | Crystal structure reveals novel activity | Enzyme engineering |
How Is 6-pyruvoyltetrahydropterin synthase activity Regulated?
PTPS activity is regulated at multiple levels. In human vascular endothelial cells, cytokines such as tumor necrosis factor-alpha and interferon-gamma increase PTPS mRNA abundance and enzyme activity, linking inflammatory signaling to BH4 synthesis. Additionally, reversible S-glutathionylation of human PTPS protects its catalytic activity under oxidative stress, providing a redox-sensitive regulatory mechanism. These findings suggest that PTPS is a dynamic node integrating inflammatory and oxidative cues to modulate BH4 availability.
6-pyruvoyltetrahydropterin synthase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTS | BH4-deficient hyperphenylalaninemia | Patient-derived iPSCs or knock-in mouse models with patient mutations |
| PTS | Endothelial dysfunction | Endothelial cell-specific knockout or overexpression in mice |
| PTPS (bacterial) | Folate biosynthesis in pathogens | Bacterial knockout strains for auxotrophy screening |
| PTPS (Plasmodium) | Malaria parasite folate pathway | Plasmodium knockout or knockdown for drug testing |
| PTS | Neurotransmitter deficiency | Neuron-specific knockout mice for behavioral studies |
PTPS Deficiency and Hyperphenylalaninemia
Mutations in the human PTS gene cause 6-pyruvoyltetrahydropterin synthase deficiency, a rare autosomal recessive disorder characterized by hyperphenylalaninemia and neurological symptoms due to impaired BH4 synthesis. This condition is a variant of phenylketonuria that requires BH4 supplementation and neurotransmitter precursors for management.
Cardiovascular and Endothelial Dysfunction
PTPS activity in vascular endothelial cells is modulated by cytokines, and reduced BH4 availability can lead to endothelial nitric oxide synthase uncoupling, oxidative stress, and vascular dysfunction. Thus, PTPS dysregulation may contribute to cardiovascular pathologies associated with inflammation.
Infectious Diseases and Folate Metabolism
Bacterial and protozoan PTPS homologues participate in folate biosynthesis, and some can replace dihydroneopterin aldolase, making them essential for pathogen survival. Inhibiting these enzymes could provide a strategy for treating infections such as malaria.
From 6-pyruvoyltetrahydropterin synthase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of PTPS loss on BH4 levels? | CRISPR knockout of PTS in cell lines (e.g., HEK293) followed by BH4 quantification |
| How do patient mutations affect PTPS activity? | Point mutation knock-in of specific PTS variants in isogenic cell lines |
| Can wild-type PTPS rescue a disease phenotype? | Knock-in of wild-type PTS into mutant cells or animal models |
| Where is PTPS localized in cells? | Tagged knock-in of PTS with fluorescent protein for imaging |
| What is the impact of PTPS overexpression on nitric oxide signaling? | Overexpression of PTS in endothelial cells followed by NO measurement |
| Which genes interact with PTPS? | CRISPR library screening for modifiers of BH4 synthesis |
How to Study the 6-pyruvoyltetrahydropterin synthase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HPLC | PTPS enzymatic activity by substrate/product quantification | Characterizing mutant enzymes |
| qRT-PCR | PTPS mRNA abundance | Cytokine regulation studies |
| Western blot | PTPS protein levels | Expression analysis |
| X-ray crystallography | Three-dimensional structure of PTPS | Structural basis of catalysis |
| Mass spectrometry | S-glutathionylation sites | Redox regulation |
| Enzyme kinetics | Kinetic parameters (Km, Vmax) | Mutant characterization |
| CRISPR screening | Genes affecting BH4 synthesis | Pathway discovery |
| Metabolomics | BH4 and related pterins | Pathway flux analysis |
Enzymatic Activity Assays
PTPS activity can be measured using HPLC-based assays that detect the conversion of 7,8-dihydroneopterin 3'-triphosphate to 6-pyruvoyl-5,6,7,8-tetrahydropterin, as described in studies of human and bacterial enzymes. These assays are essential for characterizing mutant variants and inhibitors.
Gene Expression Analysis
Quantitative RT-PCR and Western blotting are used to assess PTPS mRNA and protein levels in response to cytokines or other stimuli, as shown in human vascular endothelial cells. Such methods reveal transcriptional and post-transcriptional regulation.
Structural Biology
X-ray crystallography of PTPS homologues provides atomic-level insights into substrate binding and catalysis, facilitating comparisons between mammalian and bacterial enzymes. These structures guide rational drug design.
Redox Regulation Studies
S-glutathionylation of PTPS can be detected by immunoprecipitation and mass spectrometry, and its functional impact assessed by activity assays under oxidizing conditions. These approaches uncover post-translational regulatory mechanisms.
How CRISPR Can Be Used to Study GO:0003874 6-pyruvoyltetrahydropterin synthase activity
Knockout
CRISPR knockout of PTS in cell lines or animal models abolishes PTPS activity, leading to BH4 deficiency and accumulation of upstream metabolites. Such models are valuable for studying the consequences of BH4 loss and for testing rescue strategies.
Point Mutation
Introducing patient-specific point mutations into the endogenous PTS locus via CRISPR knock-in allows precise modeling of PTPS deficiency variants, enabling assessment of their impact on enzyme activity and BH4 levels.
Knock-in
Knock-in of tagged PTPS (e.g., GFP or HA) facilitates localization and interaction studies without altering endogenous regulation. This approach can also be used to express wild-type PTPS in mutant backgrounds for rescue experiments.
Overexpression
CRISPR activation or cDNA overexpression of PTS increases PTPS activity, which can enhance BH4 synthesis and modulate nitric oxide signaling in endothelial cells. Overexpression models help elucidate the effects of elevated PTPS on cellular physiology.
How EDITGENE Supports 6-pyruvoyltetrahydropterin synthase activity Research
Researchers studying 6-pyruvoyltetrahydropterin synthase activity-related genes often need to determine whether a candidate gene is causally involved in BH4 metabolism, endothelial function, or disease phenotypes. EDITGENE provides tailored CRISPR services to generate precisely modified cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for 6-pyruvoyltetrahydropterin synthase activity research.
Frequently Asked Questions About 6-pyruvoyltetrahydropterin synthase activity
What is 6-pyruvoyltetrahydropterin synthase activity?
It is the enzymatic activity (GO:0003874) that converts 7,8-dihydroneopterin 3'-triphosphate to 6-pyruvoyl-5,6,7,8-tetrahydropterin, a key step in tetrahydrobiopterin biosynthesis.
What genes are involved in 6-pyruvoyltetrahydropterin synthase activity?
The human PTS gene encodes the enzyme; bacterial orthologs include ygcM and other PTPS paralogs.
What diseases are associated with PTPS deficiency?
PTPS deficiency causes BH4-deficient hyperphenylalaninemia, a form of phenylketonuria with neurological symptoms.
How is PTPS activity regulated?
It is regulated by cytokines at the mRNA level and by reversible S-glutathionylation at the protein level.
What is the reaction catalyzed by PTPS?
7,8-dihydroneopterin 3'-triphosphate = 6-pyruvoyl-5,6,7,8-tetrahydropterin + H+ + triphosphate.
Do bacteria have PTPS?
Yes, bacterial PTPS orthologs exist and some have distinct catalytic activities, such as converting sepiapterin to 7,8-dihydropterin.
Why is tetrahydrobiopterin important?
BH4 is a cofactor for aromatic amino acid hydroxylases and nitric oxide synthases, critical for neurotransmitter synthesis and vascular function.
Can PTPS be targeted for drug discovery?
Yes, bacterial PTPS homologs involved in folate synthesis are potential antibiotic targets, and human PTPS is a target for modulating BH4 levels.
What methods are used to study PTPS activity?
HPLC-based activity assays, qRT-PCR, Western blot, X-ray crystallography, and mass spectrometry are commonly used.
How can CRISPR help study PTPS?
CRISPR knockout, point mutation knock-in, and overexpression models allow precise manipulation of PTS to study its function and disease relevance.
Conclusion
6-pyruvoyltetrahydropterin synthase activity (GO:0003874) is a critical enzymatic function in tetrahydrobiopterin biosynthesis, with profound implications for metabolic, cardiovascular, and infectious diseases. Understanding its regulation and structural diversity across species informs both basic biology and therapeutic development. CRISPR-based models offer powerful tools to dissect PTPS function and its role in health and disease.
References
- 1. Linscheid P et al.. 1998. Regulation of 6-pyruvoyltetrahydropterin synthase activity and messenger RNA abundance in human vascular endothelial cells.. Circulation 98(17):1703-6 PMID: 9788822
- 2. Hara S et al.. 2019. Reversible S-glutathionylation of human 6-pyruvoyl tetrahydropterin synthase protects its enzymatic activity.. J Biol Chem 294(4):1420-1427 PMID: 30514762
- 3. Seo KH et al.. 2014. Structural basis of a novel activity of bacterial 6-pyruvoyltetrahydropterin synthase homologues distinct from mammalian 6-pyruvoyltetrahydropterin synthase activity.. Acta Crystallogr D Biol Crystallogr 70(Pt 5):1212-23 PMID: 24816091
- 4. Woo HJ et al.. 2002. Escherichia coli 6-pyruvoyltetrahydropterin synthase ortholog encoded by ygcM has a new catalytic activity for conversion of sepiapterin to 7,8-dihydropterin.. FEBS Lett 523(1-3):234-8 PMID: 12123838
- 5. Werner ER et al.. 1993. Tetrahydrobiopterin and cytokines.. Proc Soc Exp Biol Med 203(1):1-12 PMID: 8475129
- 6. Pribat A et al.. 2009. 6-pyruvoyltetrahydropterin synthase paralogs replace the folate synthesis enzyme dihydroneopterin aldolase in diverse bacteria.. J Bacteriol 191(13):4158-65 PMID: 19395485
- 7. Dittrich S et al.. 2008. An atypical orthologue of 6-pyruvoyltetrahydropterin synthase can provide the missing link in the folate biosynthesis pathway of malaria parasites.. Mol Microbiol 67(3):609-18 PMID: 18093090
- 8. Kong JS et al.. 2006. 6-Pyruvoyltetrahydropterin synthase orthologs of either a single or dual domain structure are responsible for tetrahydrobiopterin synthesis in bacteria.. FEBS Lett 580(20):4900-4 PMID: 16920111
